首页
beat365中国唯一官方网站
公司简介
技术平台
公司荣誉
发展历程
管理团队
产品中心
心血管介入
外周血管介入
神经介入
非血管介入
下载专区
新闻资讯
公司新闻
行业资讯
学术论文
加入我们
公司环境
员工发展
招聘岗位
联系我们
联系方式
在线留言
EN
董事长刘青博士参加ClemsonInternationalBiomaterialsSymposium-China会议
刘青博士应GuigenZhang教授邀请参加了4月10日在美国Clemson大学举办的InternationalBiomaterialsSymposium-China, 并做了题为 “Development of Bioresorbable Tissue Scaffolds Using A New Precision Multi-axial 3D Printing Technology” 的报告
2017
04-14
公司赞助Chinese Association for Biomaterials(CAB,华人生物材料协会)活动
公司特赞助ChineseAssociationforBiomaterials(CAB,华人生物材料协会)活动
beat365中国唯一官方网站AMSorb全降解冠脉药物洗脱支架临床试验项目启动会在西安顺利召开
beat365中国唯一官方网站AMSorbTM全降解冠脉药物洗脱支架临床试验项目启动会在西安顺利召开
2016
09-09
beat365中国唯一官方网站3D打印可降解冠脉血管支架亮相欧洲心脏大会
2016年8月30日在意大利罗马召开的欧洲心脏大会上,来自北京大学第一医院霍勇教授团队的郑博教授报告了beat365中国唯一官方网站自主创新的3D打印可降解冠脉血管支架临床前的研究结果。引起与会者们的极大兴趣。
08-31
Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients
To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.
08-12
1-year outcomes with the Absorb bioresorbable scaff old in patients with coronary artery disease: a patient-level, pooled meta-analysis
Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention. Whether or not these devices are as safe and effective as drug-eluting stents within the first year after implantation is unknown.
First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China
To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA).
Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience
To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascularscaffolds have been developed to attempt to improve long-term outcomes.
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks
Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.